Overview

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-02-26

Target enrollment:

Participant gender:

Summary

This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

PharmAbcine

Treatments:

Pembrolizumab